Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03740165
Title Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43)
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

peritoneum cancer

fallopian tube cancer

ovary epithelial cancer

Therapies

Bevacizumab + Carboplatin + Paclitaxel

Carboplatin + Paclitaxel

Carboplatin + Paclitaxel + Pembrolizumab

Bevacizumab + Carboplatin + Olaparib + Paclitaxel + Pembrolizumab

Carboplatin + Olaparib + Paclitaxel + Pembrolizumab

Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA | CAN


No variant requirements are available.